Concord Biotech (BOM:543960) Total Liabilities : ₹1,741 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Concord Biotech Total Liabilities?

Concord Biotech's Total Liabilities for the quarter that ended in Mar. 2024 was ₹1,741 Mil.

Concord Biotech's quarterly Total Liabilities declined from Mar. 2023 (₹2,239.83 Mil) to Sep. 2023 (₹1,967.17 Mil) and declined from Sep. 2023 (₹1,967.17 Mil) to Mar. 2024 (₹1,740.63 Mil).

Concord Biotech's annual Total Liabilities increased from Mar. 2022 (₹2,095.72 Mil) to Mar. 2023 (₹2,239.83 Mil) but then declined from Mar. 2023 (₹2,239.83 Mil) to Mar. 2024 (₹1,740.63 Mil).

Concord Biotech Total Liabilities Historical Data

The historical data trend for Concord Biotech's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Concord Biotech Total Liabilities Chart

Concord Biotech Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

Total Liabilities

1,702.81

1,831.73

2,095.72

2,239.83

1,740.63

Concord Biotech Semi-Annual Data
	Mar20	Mar21	Mar22	Sep22	Mar23	Sep23	Mar24
Total Liabilities	Get a 7-Day Free Trial			2,095.72	-	2,239.83	1,967.17	1,740.63

Concord Biotech Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Concord Biotech's Total Liabilities for the fiscal year that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1421.554	+	(18.87	+	300.206
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,741

Total Liabilities	=	Total Assets (A: Mar. 2024 )	-	Total Equity (A: Mar. 2024 )
	=	17007.085	-	15266.455
	=	1,741

Concord Biotech's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1421.554	+	(18.87	+	300.206
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,741

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	17007.085	-	15266.455
	=	1,741

Concord Biotech Total Liabilities Related Terms

Thank you for viewing the detailed overview of Concord Biotech's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Concord Biotech (BOM:543960) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Concord Biotech Ltd (BOM:543960) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

CONCORDBIO:India

Address

Iscon Cross Road, S.G. Highway, 16th floor, B-Wing, Mondeal Heights, Ahmedabad, GJ, IND, 380015

Website

https://www.concordbiotech.com

Concord Biotech Ltd is a Research & development-driven biopharma Company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations.

Concord Biotech (BOM:543960) Headlines

No Headlines